These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 33571946)

  • 1. MAGNIMS score predicts long-term clinical disease activity-free status and confirmed disability progression in patients treated with subcutaneous interferon beta-1a.
    Sormani MP; Freedman MS; Aldridge J; Marhardt K; Kappos L; De Stefano N
    Mult Scler Relat Disord; 2021 Apr; 49():102790. PubMed ID: 33571946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1.
    Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A
    BMC Neurol; 2018 Sep; 18(1):143. PubMed ID: 30217172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and MRI efficacy of sc IFN β-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS.
    Freedman MS; Brod S; Singer BA; Cohen BA; Hayward B; Dangond F; Coyle PK
    J Neurol; 2020 Jan; 267(1):64-75. PubMed ID: 31559532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.
    Goldberg LD; Edwards NC; Fincher C; Doan QV; Al-Sabbagh A; Meletiche DM
    J Manag Care Pharm; 2009 Sep; 15(7):543-55. PubMed ID: 19739877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study.
    Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A
    BMC Neurol; 2018 May; 18(1):68. PubMed ID: 29751787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials.
    Kappos L; Wolinsky JS; Giovannoni G; Arnold DL; Wang Q; Bernasconi C; Model F; Koendgen H; Manfrini M; Belachew S; Hauser SL
    JAMA Neurol; 2020 Sep; 77(9):1132-1140. PubMed ID: 32511687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors influencing long-term outcomes in relapsing-remitting multiple sclerosis: PRISMS-15.
    Kappos L; Kuhle J; Multanen J; Kremenchutzky M; Verdun di Cantogno E; Cornelisse P; Lehr L; Casset-Semanaz F; Issard D; Uitdehaag BM
    J Neurol Neurosurg Psychiatry; 2015 Nov; 86(11):1202-7. PubMed ID: 26374702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PRISMS: the story of a pivotal clinical trial series in multiple sclerosis.
    Cohen BA; Rivera VM
    Curr Med Res Opin; 2010 Apr; 26(4):827-38. PubMed ID: 20121658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
    Coles AJ; Fox E; Vladic A; Gazda SK; Brinar V; Selmaj KW; Bass AD; Wynn DR; Margolin DH; Lake SL; Moran S; Palmer J; Smith MS; Compston DA
    Lancet Neurol; 2011 Apr; 10(4):338-48. PubMed ID: 21397567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relapse outcomes, safety, and treatment patterns in patients diagnosed with relapsing-remitting multiple sclerosis and initiated on subcutaneous interferon β-1a or dimethyl fumarate: a real-world study.
    Ernst FR; Barr P; Elmor R; Wong SL
    Curr Med Res Opin; 2017 Dec; 33(12):2099-2106. PubMed ID: 28906152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
    Hauser SL; Bar-Or A; Comi G; Giovannoni G; Hartung HP; Hemmer B; Lublin F; Montalban X; Rammohan KW; Selmaj K; Traboulsee A; Wolinsky JS; Arnold DL; Klingelschmitt G; Masterman D; Fontoura P; Belachew S; Chin P; Mairon N; Garren H; Kappos L;
    N Engl J Med; 2017 Jan; 376(3):221-234. PubMed ID: 28002679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score.
    Kunchok A; Lechner-Scott J; Granella F; Trojano M; Alroughani R; Sola P; Ferraro D; Lugaresi A; Onofrj M; Ozakbas S; Izquierdo G; Grammond P; Luis Sanchez-Menoyo J; Van Wijmeersch B; Boz C; Pucci E; McCombe P; Grand'Maison F; Spitaleri D; Vucic S; Hupperts R; Jokubaitis V; Sormani MP; Butzkueven H; Kalincik T;
    Mult Scler; 2021 Apr; 27(5):695-705. PubMed ID: 32639855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF.
    Minagara A; Murray TJ;
    Curr Med Res Opin; 2008 Apr; 24(4):1049-55. PubMed ID: 18315940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
    Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D
    Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
    Lancet; 1998 Nov; 352(9139):1498-504. PubMed ID: 9820297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis.
    Yang H; Duchesneau E; Foster R; Guerin A; Ma E; Thomas NP
    J Med Econ; 2017 Oct; 20(10):1056-1065. PubMed ID: 28703659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The STAR Study: a real-world, international, observational study of the safety and tolerability of, and adherence to, serum-free subcutaneous interferon β-1a in patients with relapsing multiple sclerosis.
    Hupperts R; Ghazi-Visser L; Martins Silva A; Arvanitis M; Kuusisto H; Marhardt K; Vlaikidis N;
    Clin Ther; 2014 Dec; 36(12):1946-1957. PubMed ID: 24811754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis.
    Andersen O; Elovaara I; Färkkilä M; Hansen HJ; Mellgren SI; Myhr KM; Sandberg-Wollheim M; Soelberg Sørensen P
    J Neurol Neurosurg Psychiatry; 2004 May; 75(5):706-10. PubMed ID: 15090564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early MRI results and odds of attaining 'no evidence of disease activity' status in MS patients treated with interferon β-1a in the EVIDENCE study.
    Coyle PK; Reder AT; Freedman MS; Fang J; Dangond F
    J Neurol Sci; 2017 Aug; 379():151-156. PubMed ID: 28716230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.
    Comi G; Kappos L; Selmaj KW; Bar-Or A; Arnold DL; Steinman L; Hartung HP; Montalban X; Kubala Havrdová E; Cree BAC; Sheffield JK; Minton N; Raghupathi K; Ding N; Cohen JA;
    Lancet Neurol; 2019 Nov; 18(11):1009-1020. PubMed ID: 31492651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.